In Q4 2023, Eventide Asset Management held 102 positions worth $3.8B. They initiated 15 new positions and exited 45. Their largest holding was XMTR ($206.3M). Portfolio value grew +11.2% versus the prior quarter.
Frequently asked questions
What stocks did Eventide Asset Management own in Q4 2023?
Eventide Asset Management held 102 biotech stocks in their 13F portfolio in Q4 2023. Their top positions include XMTR, TT, ZNTL, CLDX, ROP. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Eventide Asset Management's portfolio worth in Q4 2023?
Eventide Asset Management's tracked biotech portfolio was worth $3.8B across 102 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Eventide Asset Management buy in Q4 2023?
Eventide Asset Management initiated 15 new positions in Q4 2023, including LXEO, KRRO, ACAD, BHVN, KRYS and 10 more. They also increased 41 existing positions.
What did Eventide Asset Management sell in Q4 2023?
Eventide Asset Management fully exited 45 positions in Q4 2023, including GTM, ZIP, WEC, SYY, SPT and 40 more. They also trimmed 25 existing positions.
Is Eventide Asset Management a biotech fund?
Values-based investment firm with significant biotech allocation. Kuruvilla—a physician, engineer, and PhD—leads a team that evaluates companies on both financial merit and alignment with ethical principles. Known for holding high-conviction biotech positions alongside broader healthcare and technology investments.
Want AI analysis, insider signals, and catalyst overlays for Eventide Asset Management?
View latest Eventide Asset Management portfolio →